Overview

Price chart · mood · technical indicators

LGND

Ligand Pharmaceuticals Incorporatedstock Healthcare

Biotechnology

$234.40125.00%Current Market Mood:Strong Bullish

Market Mood

Price Range (1Y)

$102.50$247.38

Current: $234.40

Idea: EMA

1Y Return

+85.9%

Sharpe 3Y

0.85

Market Comparison

vs Healthcare Sector & Biotechnology Industry

LGND

+125.00%

1Y Performance

Fundamentals

Updated daily after market close

P/E ratio30.52Forward 26.11

EPS (TTM)$7.68103.2% YoY

Profit margin55.9%HEALTHCARE

Market cap$4.70BMid cap

Wall Street coverage

$277.60median target· current $83.60 (+232.1%)9 analysts

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

Valuation

Forward P/E: 26.11
PEG ratio: 1.53
P/B: 4.68
P/S (TTM): 17.11
EV/EBITDA: 19.36

Profitability & growth

ROE (TTM): 17.1%
Operating margin: 33.6%
Revenue growth YoY: 14.1%
Dividend yield: —
Beta: 1.07

Last earnings

May 14, 2026 · Estimate $0.98 · Reported $-0.67

Analyst estimate. Actual results often differ.

Ratios are point-in-time. Historical metrics — no guarantees about what comes next.

News & Sentiment

50 articles · sorted by date

Page 1 of 3 · 50 total

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

About Ligand Pharmaceuticals Incorporated

Company profile

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies discover and develop drugs globally. The company is headquartered in San Diego, California.

Classification

Sector: Healthcare
Industry: Biotechnology
Exchange: NASDAQ
Country: USA
Currency: USD

Company profile

HQ: 555 HERITAGE DRIVE, JUPITER, FL
Fiscal year end: December
Latest quarter: Mar 31, 2026

Market cap$4.70B

Shares outstanding$20.0M

52W high$247.38

52W low$103.43

We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer

Overview

LGND

Market Comparison

Fundamentals

Wall Street coverage

Valuation

Profitability & growth

News & Sentiment

Ligand Pharmaceuticals (Nasdaq:LGND) - Stock Analysis

Ligand Pharmaceuticals Amends XOMA Royalty Merger Agreement to Add Holding Company

Ligand (NASDAQ: LGND) amends XOMA Royalty merger, adds Nevada holding company

Stephens Investment Management Group LLC Cuts Stock Holdings in Ligand Pharmaceuticals Incorporated $LGND

UBS Group AG Purchases 31,081 Shares of Ligand Pharmaceuticals Incorporated $LGND

A Look At Ligand Pharmaceuticals (LGND) Valuation After Earnings Miss XOMA Deal And Viking TR-Beta Termination

Ligand to Participate in May Investor Conferences

Are XOMA, RMAX, KALV Obtaining Fair Deals for their Shareholders?

Vanguard Capital Management files Schedule 13G on Ligand (LGND) showing 5% stake

Vanguard reports 5.56% stake in Ligand Pharmaceuticals (NASDAQ: LGND)

[8-K] LIGAND PHARMACEUTICALS INC Reports Material Event

Ligand Pharmaceuticals to Acquire XOMA Royalty for $39 Per Share Plus CVRs

B. Metzler seel. Sohn & Co. AG Invests $1.30 Million in Ligand Pharmaceuticals Incorporated $LGND

Ligand (Nasdaq: LGND) to acquire XOMA Royalty in $739M, EPS‑accretive deal

Impax Asset Management Group plc Sells 35,000 Shares of Ligand Pharmaceuticals Incorporated $LGND

Assetmark Inc. Raises Holdings in Ligand Pharmaceuticals Incorporated $LGND

Ligand (NASDAQ: LGND) posts strong 2025 growth and seeks approval for expanded equity plan

LGND Financials: Revenue Breakdown, Margins & Competitor Comparison

Aberdeen Group plc Lowers Stock Position in Ligand Pharmaceuticals Incorporated $LGND

Ligand (NASDAQ: LGND) director exercises options, sells 2,161 common shares

About Ligand Pharmaceuticals Incorporated

Classification

Company profile

LGND

Market Comparison

LGND Market Analysis

Overview

LGND

Market Comparison

Fundamentals

Wall Street coverage

Valuation

Profitability & growth

News & Sentiment

Ligand Pharmaceuticals (Nasdaq:LGND) - Stock Analysis

Ligand Pharmaceuticals Amends XOMA Royalty Merger Agreement to Add Holding Company

Ligand (NASDAQ: LGND) amends XOMA Royalty merger, adds Nevada holding company

Stephens Investment Management Group LLC Cuts Stock Holdings in Ligand Pharmaceuticals Incorporated $LGND

UBS Group AG Purchases 31,081 Shares of Ligand Pharmaceuticals Incorporated $LGND

A Look At Ligand Pharmaceuticals (LGND) Valuation After Earnings Miss XOMA Deal And Viking TR-Beta Termination

Ligand to Participate in May Investor Conferences

Are XOMA, RMAX, KALV Obtaining Fair Deals for their Shareholders?

Vanguard Capital Management files Schedule 13G on Ligand (LGND) showing 5% stake

Vanguard reports 5.56% stake in Ligand Pharmaceuticals (NASDAQ: LGND)

[8-K] LIGAND PHARMACEUTICALS INC Reports Material Event

Ligand Pharmaceuticals to Acquire XOMA Royalty for $39 Per Share Plus CVRs

B. Metzler seel. Sohn & Co. AG Invests $1.30 Million in Ligand Pharmaceuticals Incorporated $LGND

Ligand (Nasdaq: LGND) to acquire XOMA Royalty in $739M, EPS‑accretive deal

Impax Asset Management Group plc Sells 35,000 Shares of Ligand Pharmaceuticals Incorporated $LGND

Assetmark Inc. Raises Holdings in Ligand Pharmaceuticals Incorporated $LGND

Ligand (NASDAQ: LGND) posts strong 2025 growth and seeks approval for expanded equity plan

LGND Financials: Revenue Breakdown, Margins & Competitor Comparison

Aberdeen Group plc Lowers Stock Position in Ligand Pharmaceuticals Incorporated $LGND

Ligand (NASDAQ: LGND) director exercises options, sells 2,161 common shares

About Ligand Pharmaceuticals Incorporated

Classification

Company profile

LGND

Market Comparison